INM - SDC EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients ERYTECH Pharma (NASDAQ:ERYP) +13%. Synlogic (NASDAQ:SYBX) +9% presents biomarker data for synthetic biotic medicines in phenylketonuria InMed Pharmaceuticals (NASDAQ:INM) +15%. Aprea Therapeutics (NASDAQ:APRE) +10%. SmileDirectClub (NASDAQ:SDC) +10%. Medigus (NASDAQ:MDGS) +3% on 1H results. Spectrum Pharmaceuticals (NASDAQ:SPPI) +5% presents mid-stage data for poziotinib as first-line therapy in lung cancer Ensysce Biosciences (NASDAQ:ENSC) +5%.
For further details see:
SDC, EDSA and APRE among pre market gainers